The Life Sciences Report: Briefly, tell me what you’re doing with your BioMedTracker product. How is it important for investors?
Michael Hay: With BioMedTracker we are following all the clinical drug development phases through the U.S. Food and Drug Administration (FDA) approval process. Clinical development is, obviously, a very risky undertaking, with about one in 10 products making it from phase 1 all the way to approval. There are steps or milestones along the way that each company needs to achieve before the FDA will approve a drug. Any catalyst or event that changes that 1-in-10 … [visit site to read more]